0.3238
price down icon14.79%   -0.0562
pre-market  Pre-market:  .34   0.0162   +5.00%
loading
Applied Therapeutics Inc stock is traded at $0.3238, with a volume of 13.28M. It is down -14.79% in the last 24 hours and down -15.63% over the past month. Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
See More
Previous Close:
$0.38
Open:
$0.3792
24h Volume:
13.28M
Relative Volume:
6.36
Market Cap:
$54.66M
Revenue:
-
Net Income/Loss:
$-119.76M
P/E Ratio:
-0.2399
EPS:
-1.35
Net Cash Flow:
$-55.17M
1W Performance:
-5.57%
1M Performance:
-15.63%
6M Performance:
-62.05%
1Y Performance:
-92.96%
1-Day Range:
Value
$0.3238
$0.3798
1-Week Range:
Value
$0.2998
$0.39
52-Week Range:
Value
$0.295
$10.62

Applied Therapeutics Inc Stock (APLT) Company Profile

Name
Name
Applied Therapeutics Inc
Name
Phone
212-220-9226
Name
Address
545 FIFTH AVENUE, SUITE 1400, NEW YORK, NY
Name
Employee
36
Name
Twitter
@Applied_Tx
Name
Next Earnings Date
2025-03-31
Name
Latest SEC Filings
Name
APLT's Discussions on Twitter

Compare APLT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
APLT
Applied Therapeutics Inc
0.3238 54.66M 0 -119.76M -55.17M -1.35
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
441.30 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
521.00 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.83 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
560.14 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
241.20 28.51B 3.81B -644.79M -669.77M -6.24

Applied Therapeutics Inc Stock (APLT) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-23-24 Downgrade William Blair Outperform → Mkt Perform
Dec-02-24 Downgrade UBS Buy → Neutral
Nov-29-24 Downgrade RBC Capital Mkts Outperform → Sector Perform
Jul-31-24 Initiated William Blair Outperform
Mar-26-24 Initiated RBC Capital Mkts Outperform
Feb-22-24 Initiated Leerink Partners Outperform
Jan-04-22 Downgrade Barclays Overweight → Equal Weight
Aug-27-21 Downgrade Goldman Neutral → Sell
Jun-25-21 Resumed Goldman Neutral
Oct-08-20 Initiated Truist Buy
Apr-22-20 Initiated Goldman Buy
Feb-27-20 Initiated Barclays Overweight
Jun-10-19 Initiated Citigroup Buy
Jun-10-19 Initiated Cowen Outperform
Jun-10-19 Initiated Robert W. Baird Outperform
View All

Applied Therapeutics Inc Stock (APLT) Latest News

pulisher
Jun 17, 2025

Applied Therapeutics promotes two executives to leadership roles By Investing.com - Investing.com South Africa

Jun 17, 2025
pulisher
Jun 17, 2025

Applied Therapeutics Announces New Chief Medical Officer - TipRanks

Jun 17, 2025
pulisher
Jun 17, 2025

APLT Announces Key Executive Promotions | APLT Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Applied Therapeutics Promotes Evan Bailey to Chief Medical Officer - MarketScreener

Jun 17, 2025
pulisher
Jun 17, 2025

Applied Therapeutics Announces Key Leadership Appointments | APLT Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Applied Therapeutics promotes two executives to leadership roles - Investing.com

Jun 17, 2025
pulisher
Jun 17, 2025

Applied Therapeutics Announces Key Leadership Appointments - GlobeNewswire

Jun 17, 2025
pulisher
Jun 13, 2025

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Makes New Investment in Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World

Jun 13, 2025
pulisher
Jun 13, 2025

California State Teachers Retirement System Purchases 64,316 Shares of Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World

Jun 13, 2025
pulisher
Jun 12, 2025

Applied Therapeutics holds annual stockholders meeting By Investing.com - Investing.com Canada

Jun 12, 2025
pulisher
Jun 12, 2025

Applied Therapeutics Elects New Director at Annual Meeting - TipRanks

Jun 12, 2025
pulisher
Jun 12, 2025

Applied Therapeutics holds annual stockholders meeting - Investing.com

Jun 12, 2025
pulisher
Jun 12, 2025

Two Sigma Investments LP Buys New Shares in Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

Applied Therapeutics, Inc. (NASDAQ:APLT) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat

Jun 11, 2025
pulisher
Jun 11, 2025

Analysts Set Applied Therapeutics, Inc. (NASDAQ:APLT) Target Price at $6.10 - Defense World

Jun 11, 2025
pulisher
Jun 09, 2025

Wellington Management Group LLP Boosts Holdings in Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World

Jun 09, 2025
pulisher
Jun 08, 2025

Applied Therapeutics, Inc. (NASDAQ:APLT) Shares Acquired by Millennium Management LLC - MarketBeat

Jun 08, 2025
pulisher
Jun 08, 2025

Shareholder Rights Advocates at Levi & Korsinsky Investigate Applied Therapeutics, Inc. (APLT) Regarding Possible Securities Fraud Violations - ACCESS Newswire

Jun 08, 2025
pulisher
Jun 06, 2025

Applied Therapeutics, Inc. (NASDAQ:APLT) Short Interest Update - MarketBeat

Jun 06, 2025
pulisher
Jun 05, 2025

Millennium Management LLC Boosts Holdings in Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World

Jun 05, 2025
pulisher
Jun 05, 2025

Class Action Filed Against Applied Therapeutics, Inc. (APLT)February 18, 2025 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire

Jun 05, 2025
pulisher
Jun 03, 2025

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 18, 2025 in Applied Therapeutics, Inc. LawsuitAPLT - ACCESS Newswire

Jun 03, 2025
pulisher
Jun 03, 2025

Shareholders of Applied Therapeutics, Inc. Should Contact Levi & Korsinsky Before February 18, 2025 to Discuss Your Rights – APLT - ACCESS Newswire

Jun 03, 2025
pulisher
May 31, 2025

BNP Paribas Financial Markets Grows Stake in Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World

May 31, 2025
pulisher
May 31, 2025

Janus Henderson Group PLC Sells 10,505,737 Shares of Applied Therapeutics, Inc. (NASDAQ:APLT) - MarketBeat

May 31, 2025
pulisher
May 27, 2025

Columbia Trustee Got Sued for Securities Fraud — Then Left Her Pharma Firm Under a Cloud - The Intercept

May 27, 2025
pulisher
May 26, 2025

Janus Henderson Group PLC Decreases Stake in Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World

May 26, 2025
pulisher
May 25, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Applied Therapeutics, Inc. (APLT) Investors to Inquire about Securities Investigation - ACCESS Newswire

May 25, 2025
pulisher
May 25, 2025

Price T Rowe Associates Inc. MD Sells 986,108 Shares of Applied Therapeutics, Inc. (NASDAQ:APLT) - MarketBeat

May 25, 2025
pulisher
May 24, 2025

William Blair Brokers Increase Earnings Estimates for APLT - MarketBeat

May 24, 2025
pulisher
May 24, 2025

Applied Therapeutics (NASDAQ:APLT) Upgraded by Wall Street Zen to "Sell" Rating - MarketBeat

May 24, 2025
pulisher
May 24, 2025

Vestal Point Capital LP Acquires 10,355,000 Shares of Applied Therapeutics, Inc. (NASDAQ:APLT) - MarketBeat

May 24, 2025
pulisher
May 24, 2025

Applied Therapeutics (NASDAQ:APLT) Stock Rating Upgraded by Wall Street Zen - Defense World

May 24, 2025
pulisher
May 23, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Applied Therapeutics, Inc. (APLT) Shareholders to Inquire about Securities Investigation - ACCESS Newswire

May 23, 2025
pulisher
May 23, 2025

Applied Therapeutics Inc (APLT): An Important Analyst Insights - Stocksregister

May 23, 2025
pulisher
May 22, 2025

Applied Therapeutics, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before February 18, 2025 to Discuss Your Rights – APLT - ACCESS Newswire

May 22, 2025
pulisher
May 19, 2025

Retail Traders Cheer Applied Therapeutics Data On Rare Nerve Disease Drug - MSN

May 19, 2025
pulisher
May 19, 2025

Applied Therapeutics’ Rare Disease Treatment Flunks in Late-Stage Trial - NewsBreak: Local News & Alerts

May 19, 2025
pulisher
May 19, 2025

New top-line data from Phase II/III trial of govorestat in CMT-SORD - The Pharma Letter

May 19, 2025
pulisher
May 19, 2025

Retail Traders Cheer Applied Therapeutics Data On Rare Nerve Disease Drug By Stocktwits - Investing.com India

May 19, 2025
pulisher
May 19, 2025

Applied Therapeutics Presents Full 12-Month Clinical Results and - GuruFocus

May 19, 2025
pulisher
May 18, 2025

APLT Shares Results from INSPIRE Trial on Govorestat at Peripher - GuruFocus

May 18, 2025
pulisher
May 18, 2025

APLT Shares Results from INSPIRE Trial on Govorestat at Peripheral Nerve Society Meeting | APLT Stock News - GuruFocus

May 18, 2025
pulisher
May 18, 2025

Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting - The Manila Times

May 18, 2025
pulisher
May 18, 2025

Applied Therapeutics Presents Full 12-Month Clinical - GlobeNewswire

May 18, 2025
pulisher
May 18, 2025

Breakthrough in CMT Treatment: New Clinical Data Shows First-Ever Disease Progression Slowing in 24-Month Study - Stock Titan

May 18, 2025
pulisher
May 18, 2025

Here's Why Amazon Is a Brilliant Buy Now (Hint: It's Not E-Commerce) - The Globe and Mail

May 18, 2025
pulisher
May 18, 2025

Massive News for Apple Stock Investors! - The Globe and Mail

May 18, 2025

Applied Therapeutics Inc Stock (APLT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Applied Therapeutics Inc Stock (APLT) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Funtleyder Leslie D.
See Remarks
Mar 04 '25
Sale
0.44
14,502
6,381
390,459
Chinoporos Constantine
See Remarks
Mar 04 '25
Sale
0.44
447
197
271,436
Funtleyder Leslie D.
See Remarks
Feb 06 '25
Sale
0.61
22,950
14,000
404,961
Perfetti Riccardo
Chief Medical Officer
Feb 06 '25
Sale
0.61
86,078
52,508
900,775
Chinoporos Constantine
See Remarks
Feb 06 '25
Sale
0.61
28,117
17,151
271,883
Funtleyder Leslie D.
Chief Financial Officer
Aug 22 '24
Sale
5.83
13,530
78,880
277,911
Perfetti Riccardo
Chief Medical Officer
Aug 22 '24
Sale
5.83
22,681
132,230
986,853
Shendelman Shoshana
President and CEO
Aug 13 '24
Sale
6.18
357,423
2,208,874
4,810,430
Shendelman Shoshana
President and CEO
Aug 12 '24
Sale
5.98
300,000
1,794,000
5,167,853
Shendelman Shoshana
President and CEO
Aug 14 '24
Sale
5.93
119,591
709,175
4,690,839
$20.50
price down icon 1.11%
$35.87
price up icon 1.70%
$20.60
price down icon 3.38%
$99.49
price down icon 2.21%
$106.72
price up icon 0.55%
biotechnology ONC
$241.20
price down icon 5.22%
Cap:     |  Volume (24h):